🚀 VC round data is live in beta, check it out!
Trevi Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Trevi Therapeutics and similar public comparables like Granules India, Star Lake Bioscience, Vericel, OneSource Specialty and more.
Trevi Therapeutics Overview
About Trevi Therapeutics
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Founded
2011
HQ
Employees
26
Website
Sectors
Financials (LTM)
EV
$2B
Trevi Therapeutics Financials
Trevi Therapeutics reported last 12-month revenue of — and negative EBITDA of ($56M).
In the same LTM period, Trevi Therapeutics generated — in gross profit, ($56M) in EBITDA losses, and had net loss of ($49M).
Revenue (LTM)
Trevi Therapeutics P&L
In the most recent fiscal year, Trevi Therapeutics reported revenue of — and EBITDA of ($43M).
Trevi Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($56M) | XXX | ($43M) | XXX | XXX | XXX |
| Net Profit | ($49M) | XXX | ($43M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Trevi Therapeutics Stock Performance
Trevi Therapeutics has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Trevi Therapeutics' stock price is $13.30.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 1.8% | XXX | XXX | XXX | $-0.33 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTrevi Therapeutics Valuation Multiples
Trevi Therapeutics trades at (27.2x) EV/EBITDA.
Trevi Therapeutics Financial Valuation Multiples
As of April 11, 2026, Trevi Therapeutics has market cap of $2B and EV of $2B.
Equity research analysts estimate Trevi Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Trevi Therapeutics has a P/E ratio of (34.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/EBITDA | (27.2x) | XXX | (35.6x) | XXX | XXX | XXX |
| EV/EBIT | (27.6x) | XXX | (30.8x) | XXX | XXX | XXX |
| P/E | (34.7x) | XXX | (39.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (36.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Trevi Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Trevi Therapeutics Margins & Growth Rates
Trevi Therapeutics' revenue in the last fiscal year grew by —.
Trevi Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.9M for the same period.
Trevi Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 40% | XXX | 72% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.9M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Trevi Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Granules India | XXX | XXX | XXX | XXX | XXX | XXX |
| Star Lake Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Vericel | XXX | XXX | XXX | XXX | XXX | XXX |
| OneSource Specialty | XXX | XXX | XXX | XXX | XXX | XXX |
| Harmony Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Trevi Therapeutics M&A Activity
Trevi Therapeutics acquired XXX companies to date.
Last acquisition by Trevi Therapeutics was on XXXXXXXX, XXXXX. Trevi Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Trevi Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTrevi Therapeutics Investment Activity
Trevi Therapeutics invested in XXX companies to date.
Trevi Therapeutics made its latest investment on XXXXXXXX, XXXXX. Trevi Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Trevi Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Trevi Therapeutics
| When was Trevi Therapeutics founded? | Trevi Therapeutics was founded in 2011. |
| Where is Trevi Therapeutics headquartered? | Trevi Therapeutics is headquartered in United States. |
| How many employees does Trevi Therapeutics have? | As of today, Trevi Therapeutics has over 26 employees. |
| Who is the CEO of Trevi Therapeutics? | Trevi Therapeutics' CEO is Jennifer L. Good. |
| Is Trevi Therapeutics publicly listed? | Yes, Trevi Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Trevi Therapeutics? | Trevi Therapeutics trades under TRVI ticker. |
| When did Trevi Therapeutics go public? | Trevi Therapeutics went public in 2019. |
| Who are competitors of Trevi Therapeutics? | Trevi Therapeutics main competitors are Granules India, Star Lake Bioscience, Vericel, OneSource Specialty. |
| What is the current market cap of Trevi Therapeutics? | Trevi Therapeutics' current market cap is $2B. |
| Is Trevi Therapeutics profitable? | No, Trevi Therapeutics is not profitable. |
| What is the current EBITDA of Trevi Therapeutics? | Trevi Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Trevi Therapeutics? | Current EBITDA multiple of Trevi Therapeutics is (27.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.